U.S. Markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.0977%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.3587%)
     
  • BTC-USD

    34,090.11
    +543.50 (+1.62%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

CytoSorbents, Progenity Receive Funding For Product Development

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of .5 million over 28 months.

  • The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.

  • Price Action: CTSO shares are up 0.63% at $7.96 during the market trading session on the last check Tuesday.

Progenity Inc (NASDAQ: PROG) has received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop its oral Drug Delivery System to deliver targeted therapeutics for inflammatory bowel disease.

  • Progenity's lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib.

  • Price Action: PROG shares are trading 5.7% higher at $2.49 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.